EA023193B1 - Среда для культивирования клеток для экспрессии белков adamts - Google Patents
Среда для культивирования клеток для экспрессии белков adamts Download PDFInfo
- Publication number
- EA023193B1 EA023193B1 EA201270224A EA201270224A EA023193B1 EA 023193 B1 EA023193 B1 EA 023193B1 EA 201270224 A EA201270224 A EA 201270224A EA 201270224 A EA201270224 A EA 201270224A EA 023193 B1 EA023193 B1 EA 023193B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- protein
- culture medium
- exactly
- culture
- zinc
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 99
- 102000029750 ADAMTS Human genes 0.000 title abstract 5
- 108091022879 ADAMTS Proteins 0.000 title abstract 5
- 239000006143 cell culture medium Substances 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 583
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 580
- 238000000034 method Methods 0.000 claims abstract description 391
- 230000000694 effects Effects 0.000 claims abstract description 147
- 239000000203 mixture Substances 0.000 claims abstract description 73
- 235000018102 proteins Nutrition 0.000 claims description 568
- 239000001963 growth medium Substances 0.000 claims description 559
- 210000004027 cell Anatomy 0.000 claims description 388
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 362
- 239000011701 zinc Substances 0.000 claims description 362
- 229910052725 zinc Inorganic materials 0.000 claims description 362
- 239000011575 calcium Substances 0.000 claims description 305
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 297
- 229910052791 calcium Inorganic materials 0.000 claims description 297
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 256
- 210000004962 mammalian cell Anatomy 0.000 claims description 157
- 150000007523 nucleic acids Chemical class 0.000 claims description 152
- 238000012258 culturing Methods 0.000 claims description 148
- 108020004707 nucleic acids Proteins 0.000 claims description 148
- 102000039446 nucleic acids Human genes 0.000 claims description 148
- 229920000768 polyamine Polymers 0.000 claims description 116
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical group NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 101
- 235000021120 animal protein Nutrition 0.000 claims description 56
- 239000005700 Putrescine Substances 0.000 claims description 50
- 239000000872 buffer Substances 0.000 claims description 49
- 230000010412 perfusion Effects 0.000 claims description 47
- 102000005741 Metalloproteases Human genes 0.000 claims description 46
- 108010006035 Metalloproteases Proteins 0.000 claims description 46
- 102000002938 Thrombospondin Human genes 0.000 claims description 43
- 108060008245 Thrombospondin Proteins 0.000 claims description 43
- 101800001224 Disintegrin Proteins 0.000 claims description 40
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 33
- 241000699800 Cricetinae Species 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 238000011026 diafiltration Methods 0.000 claims description 24
- 230000000737 periodic effect Effects 0.000 claims description 23
- 239000000725 suspension Substances 0.000 claims description 22
- 229960003966 nicotinamide Drugs 0.000 claims description 19
- 235000005152 nicotinamide Nutrition 0.000 claims description 19
- 239000011570 nicotinamide Substances 0.000 claims description 19
- 238000000108 ultra-filtration Methods 0.000 claims description 19
- 238000001914 filtration Methods 0.000 claims description 9
- 241000238631 Hexapoda Species 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 210000005253 yeast cell Anatomy 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000012134 supernatant fraction Substances 0.000 claims description 3
- 101000914947 Bungarus multicinctus Long neurotoxin homolog TA-bm16 Proteins 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 15
- -1 e.g. Proteins 0.000 abstract description 5
- 108091005670 ADAMTS13 Proteins 0.000 abstract 2
- 102000043853 ADAMTS13 Human genes 0.000 abstract 2
- 239000002609 medium Substances 0.000 description 107
- 238000004113 cell culture Methods 0.000 description 97
- 241001465754 Metazoa Species 0.000 description 57
- 108090000765 processed proteins & peptides Proteins 0.000 description 50
- 102000004196 processed proteins & peptides Human genes 0.000 description 47
- 229920001184 polypeptide Polymers 0.000 description 45
- 241000282414 Homo sapiens Species 0.000 description 43
- 108010038807 Oligopeptides Proteins 0.000 description 43
- 102000015636 Oligopeptides Human genes 0.000 description 43
- 230000001965 increasing effect Effects 0.000 description 28
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 239000006228 supernatant Substances 0.000 description 19
- 230000012010 growth Effects 0.000 description 18
- 239000013598 vector Substances 0.000 description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 17
- 150000001413 amino acids Chemical group 0.000 description 16
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 14
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 14
- 241000700605 Viruses Species 0.000 description 14
- 239000004017 serum-free culture medium Substances 0.000 description 14
- 238000004587 chromatography analysis Methods 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 239000011347 resin Substances 0.000 description 13
- 229920005989 resin Polymers 0.000 description 13
- 238000012832 cell culture technique Methods 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 11
- 238000001728 nano-filtration Methods 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 238000000502 dialysis Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 9
- 239000012228 culture supernatant Substances 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000013589 supplement Substances 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- 238000011210 chromatographic step Methods 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 229960003512 nicotinic acid Drugs 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 6
- 229930003537 Vitamin B3 Natural products 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 239000012538 diafiltration buffer Substances 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 235000019160 vitamin B3 Nutrition 0.000 description 6
- 239000011708 vitamin B3 Substances 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 210000003292 kidney cell Anatomy 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 238000004114 suspension culture Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 239000008366 buffered solution Substances 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000010907 mechanical stirring Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 150000003751 zinc Chemical class 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 3
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000009295 crossflow filtration Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000009465 prokaryotic expression Effects 0.000 description 3
- 239000003531 protein hydrolysate Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 206010043554 thrombocytopenia Diseases 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 102100036537 von Willebrand factor Human genes 0.000 description 3
- 229960001134 von willebrand factor Drugs 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 101800000620 Disintegrin-like Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 241001181114 Neta Species 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 230000003527 anti-angiogenesis Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000012364 cultivation method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000012526 feed medium Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940063673 spermidine Drugs 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- 241000393993 Aphia Species 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- LQVXSNNAFNGRAH-QHCPKHFHSA-N BMS-754807 Chemical compound C([C@@]1(C)C(=O)NC=2C=NC(F)=CC=2)CCN1C(=NN1C=CC=C11)N=C1NC(=NN1)C=C1C1CC1 LQVXSNNAFNGRAH-QHCPKHFHSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000036396 Dermatosparaxis Ehlers-Danlos syndrome Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 102000005561 Human Isophane Insulin Human genes 0.000 description 1
- 108010084048 Human Isophane Insulin Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 208000035888 Immune-mediated thrombotic thrombocytopenic purpura Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 102000010410 Nogo Proteins Human genes 0.000 description 1
- 108010077641 Nogo Proteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101000774655 Protobothrops mucrosquamatus Snake venom metalloproteinase TM-1 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102100030018 Tumor protein p73 Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 101710151579 Zinc metalloproteinase Proteins 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000004886 acquired thrombotic thrombocytopenic purpura Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000012365 batch cultivation Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- BNMJSBUIDQYHIN-UHFFFAOYSA-N butyl dihydrogen phosphate Chemical compound CCCCOP(O)(O)=O BNMJSBUIDQYHIN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000035118 dermatosparaxis type Ehlers-Danlos syndrome Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 102000013361 fetuin Human genes 0.000 description 1
- 108060002885 fetuin Proteins 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229910052587 fluorapatite Inorganic materials 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229940098815 novolin n Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 239000012090 serum-supplement Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940091251 zinc supplement Drugs 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/22—Zinc; Zn chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/99—Serum-free medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23047709P | 2009-07-31 | 2009-07-31 | |
| PCT/US2010/044020 WO2011014838A1 (en) | 2009-07-31 | 2010-07-30 | Cell culture medium for adamts protein expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201270224A1 EA201270224A1 (ru) | 2012-09-28 |
| EA023193B1 true EA023193B1 (ru) | 2016-05-31 |
Family
ID=42668009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201270224A EA023193B1 (ru) | 2009-07-31 | 2010-07-30 | Среда для культивирования клеток для экспрессии белков adamts |
Country Status (21)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012002151B1 (pt) * | 2009-07-31 | 2021-07-06 | Baxalta GmbH | método para expressar uma desintegrina e metaloproteinase com proteína de motivo trombospondina (adamts) |
| EA202090067A3 (ru) | 2010-07-08 | 2020-07-31 | Баксалта Инкорпорейтид | Способ получения рекомбинантного adamts13 в культуре клеток |
| LT2726600T (lt) | 2011-07-01 | 2017-05-25 | Amgen Inc. | Žinduolių ląstelių kultūra |
| ES2633960T3 (es) | 2012-10-15 | 2017-09-26 | Bristol-Myers Squibb Company | Procesos de cultivo de células de mamífero para la producción de proteínas |
| WO2014159831A1 (en) | 2013-03-13 | 2014-10-02 | Merck Sharp & Dohme Corp. | Adapted lepidopteran insect cells for the production of recombinant proteins |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| WO2015055324A1 (en) * | 2013-10-14 | 2015-04-23 | Ares Trading S.A | New medium for high performance mammalian fed-batch cultures |
| LT3926051T (lt) | 2014-06-04 | 2024-06-10 | Amgen Inc. | Žinduolių ląstelių kultūros surinkimo metodai |
| KR101867134B1 (ko) * | 2015-03-23 | 2018-06-12 | 한양대학교 산학협력단 | 포유류 세포를 이용하여 목적 물질을 고효율로 생산하기 위한 세포 배양 배지, 이를 이용한 세포 배양 방법 및 목적 물질의 생산 방법 |
| PT3298138T (pt) * | 2015-05-22 | 2022-11-02 | Dupont Nutrition Biosci Aps | Acetolactato descarboxilase |
| TWI870789B (zh) | 2015-08-04 | 2025-01-21 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| CA3031740A1 (en) | 2016-08-04 | 2018-02-08 | Baxalta Incorporated | Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome |
| WO2018128688A1 (en) * | 2016-11-04 | 2018-07-12 | Baxalta Incorporated | Adeno-associated virus purification methods |
| MX2020000228A (es) * | 2017-07-06 | 2020-08-10 | Regeneron Pharma | Proceso de cultivo celular para producir una glicoproteina. |
| KR20250016476A (ko) * | 2018-03-16 | 2025-02-03 | 젠자임 코포레이션 | 생산용 생물 반응기에서의 세포 생존력을 개선하는 방법 |
| EP3807408A4 (en) * | 2018-06-18 | 2022-03-30 | Synthetic Biologics, Inc. | METHODS OF MAKING ALKALINE PHOSPHATASE AGENTS |
| EP4037704B1 (en) | 2019-10-04 | 2025-12-03 | The Children's Medical Center Corporation | Adamts13 treatment to enhance graft survival |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| CA3159586A1 (en) | 2019-12-06 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Anti-vegf protein compositions and methods for producing the same |
| CA3173709A1 (en) | 2020-04-02 | 2021-10-07 | Friedmund BACHMANN | Adamts13 variant, compositions, and uses thereof |
| JP2023525034A (ja) | 2020-05-08 | 2023-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法 |
| JP2023526546A (ja) | 2020-05-22 | 2023-06-21 | 武田薬品工業株式会社 | コロナウイルス疾患の合併症の治療及び診断のための、ａｄａｍｔｓ１３組成物及び方法 |
| WO2021246557A1 (ko) * | 2020-06-05 | 2021-12-09 | 주식회사 프로앱텍 | 특정한 갯수의 알부민이 연결된 요산산화효소-알부민 복합체 및 이의 제조 방법 |
| CN111808822B (zh) * | 2020-07-02 | 2024-01-12 | 北京百普赛斯生物科技股份有限公司 | 细胞培养用补料液及提高重组hek293细胞蛋白表达量的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002042441A2 (en) * | 2000-11-22 | 2002-05-30 | Baxter Aktiengesellschaft | VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
| JPH0753104B2 (ja) * | 1989-02-28 | 1995-06-07 | 秀明 山田 | 細菌の培養法 |
| CZ280901B6 (cs) | 1988-10-06 | 1996-05-15 | Hideaki Yamada | Způsob kultivace bakterií |
| GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| ATE542891T1 (de) | 1994-11-10 | 2012-02-15 | Baxter Healthcare Sa | Verfahren zur herstellung von biologischen produkten in protein-freier kultur |
| CA2211630A1 (en) | 1995-02-23 | 1996-08-29 | Quest International B.V. | Peptides for tissue and cell culture media |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| AU4330597A (en) | 1996-08-30 | 1998-03-19 | Life Technologies, Inc. | Serum-free mammalian cell culture medium, and uses thereof |
| IT1285158B1 (it) | 1996-09-17 | 1998-06-03 | Angeletti P Ist Richerche Bio | Polipeptidi solubili con l'attivita' di serino-proteasi di ns3 del virus dell'epatite c, e procedimento per la loro preparazione e il |
| KR100544044B1 (ko) | 1996-10-07 | 2006-01-23 | 솔루티아인코포레이티드 | 방향족 화합물 및 벤젠의 하이드록실화 방법 및 이를 위한 반응 혼합물 |
| JP4543402B2 (ja) | 1996-10-10 | 2010-09-15 | ライフ テクノロジーズ コーポレーション | 植物由来栄養素を含む動物細胞培養培地 |
| US5804420A (en) | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
| US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| AT407255B (de) | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6406909B1 (en) | 1998-07-10 | 2002-06-18 | Chugai Seiyaku Kabushiki Kaisha | Serum-free medium for culturing animal cells |
| AT409379B (de) | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
| WO2004056976A2 (en) | 2002-12-23 | 2004-07-08 | Fuji Photo Film B.V. | Process for coating cell-culture support |
| JP2007534675A (ja) * | 2004-04-16 | 2007-11-29 | ワイス | Ａｄａｍｔｓ−８タンパク質およびその使用 |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| JP2007174948A (ja) * | 2005-12-27 | 2007-07-12 | Noritsu Koki Co Ltd | 酵素水製造装置 |
| JP4880997B2 (ja) * | 2005-12-28 | 2012-02-22 | アルフレッサファーマ株式会社 | Ａｄａｍｔｓ１３の安定化方法 |
| DK1974014T3 (en) | 2006-01-04 | 2017-06-19 | Baxalta Inc | OLIGOPEPTID-FREE CELL CULTURE MEDIA |
| CN101611268B (zh) * | 2006-12-22 | 2013-06-12 | 斯普灵格开利有限公司 | 用于空调单元的新鲜空气控制杆 |
| US20090067805A1 (en) | 2007-09-10 | 2009-03-12 | Victor Company Of Japan, Limited | Recording and reproducing device |
| NZ586250A (en) * | 2007-12-27 | 2012-11-30 | Baxter Int | Cell culture processes |
| BR112012002151B1 (pt) * | 2009-07-31 | 2021-07-06 | Baxalta GmbH | método para expressar uma desintegrina e metaloproteinase com proteína de motivo trombospondina (adamts) |
-
2010
- 2010-07-30 BR BR112012002151-6A patent/BR112012002151B1/pt active IP Right Grant
- 2010-07-30 AU AU2010278751A patent/AU2010278751B2/en active Active
- 2010-07-30 HR HRP20160783TT patent/HRP20160783T1/hr unknown
- 2010-07-30 ES ES10740810.6T patent/ES2583258T3/es active Active
- 2010-07-30 CA CA2769361A patent/CA2769361A1/en not_active Abandoned
- 2010-07-30 BR BR122021005965-9A patent/BR122021005965B1/pt active IP Right Grant
- 2010-07-30 EA EA201270224A patent/EA023193B1/ru not_active IP Right Cessation
- 2010-07-30 CN CN201080042028.1A patent/CN102549145B/zh active Active
- 2010-07-30 CN CN201510186244.8A patent/CN104962539B/zh active Active
- 2010-07-30 KR KR1020177018298A patent/KR101808496B1/ko active Active
- 2010-07-30 US US12/847,999 patent/US8313926B2/en active Active
- 2010-07-30 KR KR1020127005425A patent/KR101573972B1/ko active Active
- 2010-07-30 PL PL10740810.6T patent/PL2459702T3/pl unknown
- 2010-07-30 IN IN801DEN2012 patent/IN2012DN00801A/en unknown
- 2010-07-30 MX MX2012001261A patent/MX2012001261A/es active IP Right Grant
- 2010-07-30 EP EP10740810.6A patent/EP2459702B1/en active Active
- 2010-07-30 SG SG2012006839A patent/SG178194A1/en unknown
- 2010-07-30 WO PCT/US2010/044020 patent/WO2011014838A1/en not_active Ceased
- 2010-07-30 KR KR1020157009715A patent/KR101574056B1/ko active Active
- 2010-07-30 PT PT107408106T patent/PT2459702T/pt unknown
- 2010-07-30 KR KR1020177035177A patent/KR101912552B1/ko active Active
- 2010-07-30 JP JP2012523110A patent/JP5451884B2/ja active Active
- 2010-07-30 KR KR1020157033595A patent/KR101756354B1/ko active Active
- 2010-07-30 NZ NZ597727A patent/NZ597727A/xx unknown
- 2010-07-30 SI SI201031238A patent/SI2459702T1/sl unknown
- 2010-07-30 HU HUE10740810A patent/HUE029110T2/en unknown
-
2012
- 2012-01-27 MX MX2013009470A patent/MX344970B/es unknown
- 2012-02-27 CO CO12033821A patent/CO6501191A2/es unknown
- 2012-09-19 US US13/622,939 patent/US8759026B2/en active Active
-
2014
- 2014-05-13 US US14/276,819 patent/US9127265B2/en active Active
-
2015
- 2015-07-23 US US14/807,745 patent/US9441216B2/en active Active
-
2016
- 2016-05-06 JP JP2016093240A patent/JP6511007B2/ja active Active
- 2016-08-09 US US15/232,626 patent/US10072254B2/en active Active
-
2018
- 2018-01-26 JP JP2018011373A patent/JP6567707B2/ja active Active
- 2018-09-08 US US16/125,688 patent/US10724024B2/en active Active
-
2019
- 2019-07-31 JP JP2019141485A patent/JP6883071B2/ja active Active
-
2020
- 2020-06-16 US US16/903,185 patent/US11254921B2/en active Active
-
2021
- 2021-05-07 JP JP2021079239A patent/JP7083059B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002042441A2 (en) * | 2000-11-22 | 2002-05-30 | Baxter Aktiengesellschaft | VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE |
Non-Patent Citations (4)
| Title |
|---|
| "Technical Resources - Media Formulations D-MEM/F-12 (1X) liquid 1:1". [Online] 2010, XP002599526, Invitrogen by Life Technologies Retrieved from the Internet: URL:http://www.invitrogen.com/site/us/en/home/support/Product-Technical-Resources/media_formulation.214.html> [retrieved on 2010-09-07] * |
| BEVITT D.J. ET AL.: "Expression of ADAMTS metalloproteinases in the retinal pigment epithelium derived cell line ARPE-19: transcriptional regulation by TNFalpha", BIOCHIMICA ET BIOPHYSICA ACTA. GENE STRUCTURE AND EXPRESSION, ELSEVIER, AMSTERDAM, NL LNKD-DOI:10.1016/S0167-4781(03)00047-2, vol. 1626, no. 1-3, 15 April 2003 (2003-04-15), pages 83-91, XP004420599, ISSN: 0167-4781, page 84, column 2, paragraph 1 * |
| DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2002 (2002-11-16), SCHEIFLINGER FRIEDRICH ET AL.: "Recombinant Expression and Functional Characterization of the von Willebrand Factor-Cleaving Protease (ADAMTS13)." XP002599525, Database accession no. PREV200300356456, abstract & BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), page, Abstract No. 475, 44TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; PHILADELPHIA, PA, USA; DECEMBER 06-10, 2002, ISSN: 0006-4971 * |
| PLAIMAUER B. ET AL.: "Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13)", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, LNKD-DOI:10.1182/BLOOD-2002-05-1397, vol. 100, no. 10, 15 November 2002 (2002-11-15), pages 3626-3632, XP002979372, ISSN: 0006-4971, cited in the application, page 3628, column 1, paragraph 4 - column 2, paragraph 1 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA023193B1 (ru) | Среда для культивирования клеток для экспрессии белков adamts | |
| AU2017261523B2 (en) | Cell culture medium for adamts protein expression | |
| AU2019279943B2 (en) | Cell culture medium for adamts protein expression | |
| JP5936232B6 (ja) | Ａｄａｍｔｓタンパク質発現のための細胞培養培地 | |
| HK1171790B (en) | Cell culture medium for adamts protein expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Registration of transfer of a eurasian patent by assignment | ||
| PC4A | Registration of transfer of a eurasian patent by assignment | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KG TJ TM |